- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264209
Smart After-Care in Patients With Prostate Cancer
September 28, 2017 updated by: Ji Youl Lee
Smart After-Care in Patients With Prostate Cancer: a Randomized Controlled Trial
This study aims to examine whether Smart After-Care service (Internet-and mobile-based lifestyle intervention) has an effect on patients' satisfaction and clinical outcomes in patients with prostate cancer on androgen deprivation therapy.
Patients with prostate cancer on androgen deprivation therapy will participate in the study.
The study design is a randomized controlled trial.
The patients were randomly assigned to intervention or usual care groups.
Intervention patients received Smart After-Care service for 3 months.
Primary endpoint was an increase in patients' physical function as assessed using 2 minute walking test.
Secondary endpoints included improvement in muscle strength, short physical performance battery, body composition, and health-related quality of life.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
After-care is a process targeted towards restoration or maintenance of the physical, mental, intellectual and social abilities of an individual affected by cancer.
Internet-and mobile-based lifestyle intervention have emerged as potential modalities to complement and increase accessibility to after-care.
In order to meet the growing need for after-care services, we developed a Smart after-care system that will assess the efficacy of a web-based smartphone-enabled intervention.
The system provided specialized tools on after-care of prostate cancer including information on nutrition, physical activity, medication adherence, and mobile device that can connect to the smartphone.
Patients with prostate cancer on androgen deprivation therapy will be screened for having adequate musculoskeletal and cardiopulmonary function.The study design is a randomized controlled trial.
The patients were randomly assigned to intervention or usual care groups.
Intervention patients received Smart After-Care management for 3 months.
Primary endpoint was an increase in patients' physical function as assessed using 2 minute walking test.
Secondary endpoints included improvement in muscle strength, short physical performance battery, body composition, and health-related quality of life.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 06591
- Recruiting
- Seoul St. Mary's hospital
-
Contact:
- Ji Youl Lee
- Phone Number: 82-2-2258-6076
- Email: uroljy@catholic.ac.kr
-
Contact:
- Yong Hyun Park
- Phone Number: 82-2-2258-6076
- Email: lestat04@catholic.ac.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males diagnosed with prostate cancer
- Current treatment with ADT (GnRH agonist/antagonist with or without antiandrogen) for a minimum of 6 months after randomization
- Having Android smartphone
Exclusion Criteria:
- Having another (active) malignant disease within 3 month before randomization
- Having severe cardiopulmonary disease
- Having bone pain due to bone metastasis, (or) pathologic fracture
- Receiving total knee replacement arthroplasty, (or) total hip replacement arthroplasty
- No permission from treating/study physician to participate in exercise
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention: Case management
Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
|
Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone.
Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
|
No Intervention: Control: usual care
Usual care is provided with life style intervention including exercise and nutrition by printed materials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical function (2 minute walking test)
Time Frame: 3 months after randomization
|
Cardiorespiratory endurance was examined by 2MWT performed on a 15.2-m hallway out-and-back course.
Patients were instructed to walk as fast as they could until asked to stop at 2 min; the distance covered was recorded.
|
3 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in muscle strength
Time Frame: 3 months after randomization
|
A handgrip strength test was used to assess upper extremity muscle strength using a hand-held dynamometer.
Patients were instructed to apply maximal power for 3 s with the shoulder adducted and neutrally rotated, elbow flexed at 90°, and the forearm and wrist in a neutral position.
Three attempts were given with each hand and the best score (kg) for each was recorded.
A 30-s chair stand test was used as a measure of lower extremity muscle strength.
Each patient was seated in the middle of the chair (seat height of 40 cm, without armrests but with a backrest) with their back straight and both arms folded across their chest.
The patients were instructed to stand up and sit down repetitively and encouraged to complete as many full stands as possible for 30 s while the instructor kept count.
|
3 months after randomization
|
Changes in short physical performance battery
Time Frame: 3 months after randomization
|
The SPPB is calculated from three components: the ability to stand for up to 10 seconds with feet positioned in three ways (together side-by-side, semi-tandem and tandem); time to complete a 3-m or 4-m walk; and time to rise from a chair five times.
|
3 months after randomization
|
Changes in body composition
Time Frame: 3 months after randomization
|
weight in kilograms, height in meters, body fat mass in kilograms, skeletal muscle mass in kilograms
|
3 months after randomization
|
Changes in health-related quality of life by EORTC QLQ-C30
Time Frame: 3 months after randomization
|
Units on a Scale
|
3 months after randomization
|
Changes in health-related quality of life by EORTC QLQ-PR25.
Time Frame: 3 months after randomization
|
Units on a Scale
|
3 months after randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ji Youl Lee, MD, PhD, Seoul St. Mary's hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2017
Primary Completion (Anticipated)
August 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
August 22, 2017
First Submitted That Met QC Criteria
August 24, 2017
First Posted (Actual)
August 29, 2017
Study Record Updates
Last Update Posted (Actual)
October 2, 2017
Last Update Submitted That Met QC Criteria
September 28, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KC17FNDI0557
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Smart After-Care (Mobile health)
-
Butler HospitalNational Institute of Mental Health (NIMH)Completed
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical CenterRecruitingPost Traumatic Stress DisorderUnited States
-
Monash UniversityCaring Pharmacy; Bionime Corporation; Tigas PharmaActive, not recruiting
-
National University of SingaporeSaglik Bilimleri UniversitesiRecruitingMaternal and Child HealthCambodia
-
Gadjah Mada UniversityUniversitas Islam IndonesiaRecruitingPreDiabetes | Prediabetic StateIndonesia
-
George Washington UniversityCompleted
-
Akdeniz UniversityCompletedAdolescent | Asthma in Children | Self Efficacy | Nursing CareTurkey
-
Korea UniversityCompletedHypertension | Obesity | DiabetesKorea, Republic of
-
Clemson UniversityU.S. Army Medical Research and Development Command; Madigan Army Medical CenterCompletedDiabetes Mellitus, Type 2United States
-
University of OttawaCompleted